0.75

3.92% 0.0283

After Hours: 29.72 28.97 +3,863%

Relmada Therapeutics Inc (RLMD)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Relmada Therapeutics Inc stock is traded at $0.75, with a volume of 584.29K. It is up +3.92% in the last 24 hours and up +163.99% over the past month. Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Previous Close:

$0.7217

Open:

$0.7275

24h Volume:

584.29K

Relative Volume:

0.35

Market Cap:

$24.89M

Revenue:

Net Income/Loss:

$-98.79M

P/E Ratio:

-0.2294

EPS:

-3.27

Net Cash Flow:

$-51.66M

1W Performance:

+17.30%

1M Performance:

+163.99%

6M Performance:

-75.17%

1Y Performance:

-75.33%

1-Day Range:

$0.692

$0.7689

1-Week Range:

$0.6204

$0.7689

52-Week Range:

$0.2404

$4.47

Relmada Therapeutics Inc Stock (RLMD) Company Profile

Name

Relmada Therapeutics Inc

Sector

Healthcare (1170)

Industry

Biotechnology (667)

Phone

646 876 3459

Address

2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY

Employee

Twitter

@relmada

Next Earnings Date

2025-03-25

Latest SEC Filings

RLMD's Discussions on Twitter

Compare RLMD with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RLMD	3.03	0	0	0	0	0.00
GOODO Gladstone Commercial Corporation	20.43	372.90M	0	0	0	0.00
JUNE Dhandho Junoon Etf	11.50	190.93M	0	0	0	0.00
SHMD Schmid Group N V	2.76	131.34M	0	0	0	0.00
PSNYW Polestar Automotive Holding Uk	0.1601	350.74M	2.07B	-1.42B	-1.37B	-0.6765
MOBBW Mobilicom Limited Warrants	0.4197	636.80M	0	0	0	0.00

Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-05-24	Downgrade	Mizuho	Outperform → Neutral
Sep-17-24	Upgrade	Jefferies	Hold → Buy
Jun-05-24	Downgrade	Goldman	Neutral → Sell
Oct-14-22	Downgrade	Goldman	Buy → Neutral
Oct-14-22	Downgrade	Guggenheim	Buy → Neutral
Oct-14-22	Downgrade	Truist	Buy → Hold
Oct-13-22	Downgrade	Oppenheimer	Outperform → Perform
Nov-18-21	Initiated	Mizuho	Buy
May-20-21	Resumed	Goldman	Buy
Oct-28-20	Downgrade	Goldman	Buy → Neutral
Jul-14-20	Initiated	Oppenheimer	Outperform
May-04-20	Initiated	SunTrust	Buy
Apr-21-20	Initiated	Goldman	Buy
Jan-27-20	Initiated	Jefferies	Buy
Jan-10-20	Initiated	SVB Leerink	Outperform
Dec-16-19	Initiated	Guggenheim	Buy

View All

Relmada Therapeutics Inc Stock (RLMD) Latest News

May 27, 2025

Relmada Therapeutics Holds Annual Stockholders Meeting - TipRanks

May 27, 2025

May 24, 2025

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Receives Consensus Rating of “Hold” from Brokerages - Defense World

May 24, 2025

Relmada Therapeutics (NASDAQ:RLMD) Lowered to Strong Sell Rating by Wall Street Zen - Defense World

May 24, 2025

May 20, 2025

RELMADA THERAPEUTICS Executives Make Significant Stock Purchases in May 2025 - TradingView

May 20, 2025

May 16, 2025

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Relmada Therapeutics (RLMD) and Roivant Sciences (ROIV) - The Globe and Mail

May 16, 2025

May 15, 2025

Relmada Therapeutics’ Earnings Call: Promising Data Amid Financial Concerns - TipRanks

May 15, 2025

May 13, 2025

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2025 Earnings Call Transcript - Insider Monkey

May 13, 2025

Earnings call transcript: Relmada Therapeutics’ Q1 2025 results miss EPS expectations - Investing.com

May 13, 2025